News

News
pneumococcal vaccine

Merck's challenge to Pfizer's Prevnar grows

Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu

News
Medicxi co-founder and partner Francesco De Rubertis

Medicxi primes its latest $400m biotech fund

Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting 'asset-centric' companies at all stages of